MetaCap

BioCryst Pharmaceuticals (BCRX) vs Hemab Therapeutics (COAG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioCryst Pharmaceuticals is the larger company by market cap ($1.86 billion vs $1.84 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCRX-21.44%COAG+15.56%
+66%+18%-31%
May 1, 20261 yearNov 20, 2026
BCRX-21.44%COAG+15.56%
+66%+18%-31%
Apr 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCRX versus COAG key metrics
MetricBCRXCOAG
Share price$7.22$39.29
Market cap$1.86B$1.84B
1-day change-1.37%-1.43%
YTD return-7.44%—
1-year return+3.59%—
5-year return-42.15%—
Forward P/E8.44—
EPS (TTM)$-1.28$-3.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$874.84M—
Revenue growth (YoY)+94.10%—
Net income (latest FY)$263.86M—
Gross margin97.82%—
Operating margin38.98%—
Net margin30.16%—
52-week high$11.22$55.42
52-week low$6.23$23.00
Distance from 52-week high-35.65%-29.11%
Analyst consensusbuystrong_buy
Avg. price target upside+183.24%+60.35%
Average volume4.97M495.96K
Shares outstanding257.30M46.73M
Employees43559
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BioCryst Pharmaceuticals

BCRX stock →

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees

About Hemab Therapeutics

COAG stock →

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees

BCRX vs COAG FAQ

Which is bigger, BioCryst Pharmaceuticals or Hemab Therapeutics?

BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $1.86B compared with $1.84B for Hemab Therapeutics (COAG).

Are BioCryst Pharmaceuticals and Hemab Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons